Here, our work shows that the combination therapy targeting the sialoglycan/Siglec pathway and PD-1 or CTLA-4 inhibition induces tumor control in different preclinical mouse models and increases T cell activation in primary patient tumor samples. Here, RPL17 is linked to neoplasm.